Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of “Moderate Buy” by Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been assigned an average rating of “Moderate Buy” from the fourteen analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $117.8182.

A number of equities research analysts have recently weighed in on the company. TD Cowen restated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Raymond James Financial reiterated a “strong-buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wedbush boosted their price objective on Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Finally, Wall Street Zen upgraded shares of Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th.

Insider Transactions at Dianthus Therapeutics

In related news, EVP Simrat Randhawa sold 26,530 shares of the stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $90.62, for a total value of $2,404,148.60. Following the transaction, the executive vice president directly owned 4,000 shares in the company, valued at $362,480. This represents a 86.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Ryan Savitz sold 31,249 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the completion of the transaction, the executive vice president directly owned 31,249 shares in the company, valued at approximately $3,157,086.47. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 87,779 shares of company stock worth $7,985,235 in the last quarter. 3.02% of the stock is owned by company insiders.

Institutional Trading of Dianthus Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in DNTH. PNC Financial Services Group Inc. grew its holdings in Dianthus Therapeutics by 0.4% during the first quarter. PNC Financial Services Group Inc. now owns 37,360 shares of the company’s stock valued at $3,135,000 after purchasing an additional 139 shares during the period. First Horizon Corp acquired a new stake in Dianthus Therapeutics in the first quarter worth $32,000. Virtus Investment Advisers LLC raised its holdings in Dianthus Therapeutics by 7.1% in the fourth quarter. Virtus Investment Advisers LLC now owns 6,315 shares of the company’s stock worth $260,000 after purchasing an additional 416 shares during the period. Royal Bank of Canada boosted its position in shares of Dianthus Therapeutics by 36.9% during the fourth quarter. Royal Bank of Canada now owns 2,012 shares of the company’s stock worth $82,000 after purchasing an additional 542 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Dianthus Therapeutics by 4.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after purchasing an additional 618 shares in the last quarter. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Price Performance

DNTH stock opened at $103.87 on Friday. The company has a 50 day moving average price of $90.72 and a 200 day moving average price of $75.95. Dianthus Therapeutics has a fifty-two week low of $18.08 and a fifty-two week high of $107.99. The stock has a market capitalization of $5.68 billion, a PE ratio of -25.15 and a beta of 1.20.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.40 million. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%. As a group, equities analysts expect that Dianthus Therapeutics will post -3.82 earnings per share for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.